Biology Reference
In-Depth Information
Hoshijima M, Ikeda Y, Iwanaga Y et al (2002) Chronic suppression of heart-failure progression by
a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.
Nat Med 8:864-871
Iwanaga Y, Hoshijima M, Gu Y et al (2004) Chronic phospholamban inhibition prevents progres-
sive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest
113:727-736
Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1985) Positive inotropic and vasodi-
lator actions of milrinone in patients with severe congestive heart failure. Dose-response
relationships and comparison to nitroprusside. J Clin Invest 75:643-649
Juhaszova M, Zorov DB, Kim SH et al (2004) Glycogen synthase kinase-3beta mediates conver-
gence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin
Invest 113:1535-1549
Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardio-
vascular regulation. Circ Res 101:1084-1095
Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello VC (2000) Functions of the N-terminal
region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem275:12331-12338
Lehnart SE, Wehrens XH, Reiken S et al (2005) Phosphodiesterase 4D deficiency in the ryano-
dine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35
Lim SY, Davidson SM, Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning:
the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 75:530-535
Lin CS, Chow S, Lau A, Tu R, Lue TF (2002) Human PDE5A gene encodes three PDE5 isoforms
from two alternate promoters. Int J Impot Res 14:15-24
Liu Y, Sato T, O'Rourke B, Marban E (1998) Mitochondrial ATP-dependent potassium channels:
novel effectors of cardioprotection? Circulation 97:2463-2469
Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from
the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell
101:365-376
Meyer M, Belke DD, Trost SU et al (2004) A recombinant antibody increases cardiac contractility
by mimicking phospholamban phosphorylation. FASEB J 18:1312-1314
Miller CL, Oikawa M, Cai Y et al (2009) Role of Ca2+/calmodulin-stimulated cyclic nucleotide
phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105:956-964
Minamisawa S, Hoshijima M, Chu G et al (1999) Chronic phospholamban-sarcoplasmic reticulum
calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.
Cell 99:313-322
Movsesian MA, Bristow MR (2005) Alterations in cAMP-mediated signaling and their role in the
pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol 68:25-48
Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmic reticulum-
associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing
human hearts. J Clin Invest 88:15-19
Movsesian M, Stehlik J, Vandeput F, Bristow MR (2009) Phosphodiesterase inhibition in heart
failure. Heart Fail Rev 14:255-263
Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (2008) Sustained soluble guanylate cyclase
stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by
sildenafil. J Pharmacol Exp Ther 326:380-387
Nagayama T, Hsu S, Zhang M et al (2009) Sildenafil stops progressive chamber, cellular, and
molecular remodeling and improves calcium handling and function in hearts with pre-existing
advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207-215
Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in
the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5
improves contractility. Circulation 116:238-248
Nanas JN, Tsagalou EP, Kanakakis J et al (2004) Long-term intermittent dobutamine infusion,
combined with oral amiodarone for end-stage heart failure: a randomized double-blind study.
Chest 125:1198-1204
Search WWH ::




Custom Search